Developing Novel Drug Candidates

Summit Therapeutics is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile.

Our goal is to become a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.

We are listed on the AIM market of the London Stock Exchange (symbol ‘SUMM’) and the NASDAQ Global Market (symbol ‘SMMT’).  Further information is available in our dedicated Investor Relations section.

Stocks

Share Price

LSE: SUMM
162.50p -2.50
at 12:32pm GMT 15 Dec 2017

NASDAQ: SMMT
$10.26 -0.03
at 04:00pm ET 15 Dec 2017